264 related articles for article (PubMed ID: 21914505)
1. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis.
Vegter S; Tolley K; Keith MS; Postma MJ
Value Health; 2011; 14(6):852-8. PubMed ID: 21914505
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
Park H; Rascati KL; Keith MS; Hodgkins P; Smyth M; Goldsmith D; Akehurst R
Value Health; 2011 Dec; 14(8):1002-9. PubMed ID: 22152168
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
Goto S; Komaba H; Moriwaki K; Fujimori A; Shibuya K; Nishioka M; Kim JI; Yoshiya K; Shin J; Hasegawa H; Taniguchi M; Fujii H; Nishi S; Kamae I; Fukagawa M
Clin J Am Soc Nephrol; 2011 Jun; 6(6):1375-84. PubMed ID: 21551021
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
Habbous S; Przech S; Martin J; Garg AX; Sarma S
Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
[TBL] [Abstract][Full Text] [Related]
6. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease.
Brennan A; Akehurst R; Davis S; Sakai H; Abbott V
Value Health; 2007; 10(1):32-41. PubMed ID: 17261114
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
[TBL] [Abstract][Full Text] [Related]
9. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
Keith MS; Wilson RJ; Preston P; Copley JB
Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
[TBL] [Abstract][Full Text] [Related]
10. Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
Keith MS; Sibbel S; Copley JB; Wilson RJ; Brunelli SM
Clin Ther; 2014 Oct; 36(10):1431-42.e1. PubMed ID: 25150194
[TBL] [Abstract][Full Text] [Related]
11. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
Chan WL; Rounsley K; Chapman E; Collings K; Dale C; De Waal S; Patel V; Tanner J; Turner E; Moore J; Borrows R
J Ren Nutr; 2010 Jul; 20(4):270-7. PubMed ID: 20362463
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of sevelamer in patients with end-stage renal disease.
Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
[TBL] [Abstract][Full Text] [Related]
13. Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients.
Nguyen HV; Bose S; Finkelstein E
BMC Nephrol; 2016 Apr; 17(1):45. PubMed ID: 27121505
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis.
Gros B; Galán A; González-Parra E; Herrero JA; Echave M; Vegter S; Tolley K; Oyagüez I
Health Econ Rev; 2015 Dec; 5(1):49. PubMed ID: 26062537
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
[TBL] [Abstract][Full Text] [Related]
16. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
St Peter WL; Wazny LD; Weinhandl ED
Am J Kidney Dis; 2018 Feb; 71(2):246-253. PubMed ID: 29195858
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
Gutzwiller FS; Pfeil AM; Ademi Z; Blank PR; Braunhofer PG; Szucs TD; Schwenkglenks M
Pharmacoeconomics; 2015 Dec; 33(12):1311-24. PubMed ID: 26334991
[TBL] [Abstract][Full Text] [Related]
18. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
Shigematsu T; Tokumoto A; Nakaoka A; Arisaka H
Ther Apher Dial; 2011 Apr; 15(2):176-84. PubMed ID: 21426511
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
[TBL] [Abstract][Full Text] [Related]
20. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
